Drug Discovery Intelligence From Public Evidence
VexASI monitors research expansion, platform adoption, lab operations, computational hiring, and partnership signals for teams selling into drug discovery organizations.
Where Signals Emerge
Drug discovery decisions move through research leadership, computational teams, lab operations, data infrastructure, and executive stakeholders.
Program and Pipeline Activity
Therapeutic-area expansion, grants, collaborations, research partnerships, and public scientific activity that point to operational needs.
Scientific and Technical Hiring
Signals in computational biology, cheminformatics, AI/ML discovery, bioinformatics, lab automation, informatics, and data engineering roles.
Systems and Workflow Evidence
Clues tied to ELN, LIMS, research data platforms, automation systems, knowledge graphs, and AI-enabled discovery infrastructure.
Why It Matters
Scientific organizations often leave procurement-relevant evidence across hiring posts, partnership language, conference abstracts, and platform announcements.
VexASI helps GTM teams understand where research operations are changing before a formal vendor conversation is obvious.
The intelligence is commercial and operational. It is not medical advice, clinical guidance, therapeutic evaluation, or regulatory advice.
Sample Brief Inputs
- Computational biology and AI discovery hiring
- Lab automation and informatics expansion
- Research collaborations and platform partnerships
- ELN, LIMS, data platform, or workflow clues
- Scientific conference and publication activity
Need drug discovery signal coverage?
Use a focused sector brief to connect research evidence, platform movement, and commercial timing.